AR047154A1 - Tratamiento del insomnio en pacientes humanos administrandoles una cantidad diaria de gaboxadol - Google Patents

Tratamiento del insomnio en pacientes humanos administrandoles una cantidad diaria de gaboxadol

Info

Publication number
AR047154A1
AR047154A1 ARP040104752A ARP040104752A AR047154A1 AR 047154 A1 AR047154 A1 AR 047154A1 AR P040104752 A ARP040104752 A AR P040104752A AR P040104752 A ARP040104752 A AR P040104752A AR 047154 A1 AR047154 A1 AR 047154A1
Authority
AR
Argentina
Prior art keywords
insomnia
treatment
gaboxadol
administrandoles
daily amount
Prior art date
Application number
ARP040104752A
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34684447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR047154(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR047154A1 publication Critical patent/AR047154A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un método para el tratamiento del insomnio en un paciente humano que lo necesita mediante la administracion a dicho paciente de una cantidad diaria de gaboxadol, cantidad que es efectiva para el tratamiento de insomnio. Reivindicacion 10: El uso del gaboxadol para la preparacion de un medicamento para el tratamiento del insomnio en un paciente humano, donde el medicamento se presenta en forma de dosis oral.
ARP040104752A 2003-12-18 2004-12-17 Tratamiento del insomnio en pacientes humanos administrandoles una cantidad diaria de gaboxadol AR047154A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200301877 2003-12-18

Publications (1)

Publication Number Publication Date
AR047154A1 true AR047154A1 (es) 2006-01-11

Family

ID=34684447

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104752A AR047154A1 (es) 2003-12-18 2004-12-17 Tratamiento del insomnio en pacientes humanos administrandoles una cantidad diaria de gaboxadol

Country Status (17)

Country Link
EP (1) EP1720547A1 (es)
JP (1) JP2007515415A (es)
KR (1) KR20060103335A (es)
CN (1) CN1893942A (es)
AR (1) AR047154A1 (es)
AU (1) AU2004298313A1 (es)
BR (1) BRPI0415893A (es)
CA (1) CA2550610A1 (es)
EA (1) EA200600989A1 (es)
IL (1) IL176239A0 (es)
IS (1) IS8390A (es)
MX (1) MXPA06006685A (es)
NO (1) NO20063320L (es)
SG (1) SG133601A1 (es)
TW (1) TW200528098A (es)
WO (1) WO2005058313A1 (es)
ZA (1) ZA200602762B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
EP1906953A4 (en) * 2005-04-29 2009-05-20 Lundbeck & Co As H ACID AND BASE SALT FORMS OF GABOXADOL
IL256912B2 (en) 2015-07-17 2024-01-01 Ovid Therapeutics Inc Methods of treating developmental disorders with gaboxadol
CN111328282A (zh) * 2017-09-12 2020-06-23 奥维德医疗公司 加波沙朵在治疗发作性睡病中的用途
WO2020061410A1 (en) 2018-09-20 2020-03-26 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
CN113423399A (zh) * 2018-12-17 2021-09-21 奥维德医疗公司 加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途
CN114786669A (zh) 2019-12-18 2022-07-22 奥维德医疗公司 用于1p36缺失综合征的治疗性治疗的加波沙朵

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19525598C2 (de) * 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
WO2002094225A1 (en) * 2001-05-21 2002-11-28 H. Lundbeck A/S Granular preparations of gaboxadol

Also Published As

Publication number Publication date
NO20063320L (no) 2006-07-18
WO2005058313A1 (en) 2005-06-30
KR20060103335A (ko) 2006-09-28
IL176239A0 (en) 2006-10-05
AU2004298313A1 (en) 2005-06-30
BRPI0415893A (pt) 2007-01-09
EP1720547A1 (en) 2006-11-15
SG133601A1 (en) 2007-07-30
CA2550610A1 (en) 2005-06-30
JP2007515415A (ja) 2007-06-14
EA200600989A1 (ru) 2006-10-27
MXPA06006685A (es) 2006-08-23
IS8390A (is) 2006-03-30
ZA200602762B (en) 2007-06-27
TW200528098A (en) 2005-09-01
CN1893942A (zh) 2007-01-10

Similar Documents

Publication Publication Date Title
MX2009002196A (es) Oblea de buprenorfina para terapia de sustitucion de farmacos.
AR050418A1 (es) Dosificacion fija de anticuerpos her
AR065580A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
PT1173178E (pt) Composicao compreendendo apomorfina e sildenafil e utilizacao da mesma para o tratamento da disfuncao erectil
CY1116727T1 (el) Θεραπεια πολλαπλης σκληρυνσης me laquinimod
PE20170302A1 (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
ECSP045069A (es) Uso de flibanserina en el tratamiento de trastornos sexuales
JP2006501240A5 (es)
CO6150188A2 (es) Uso de teencteplasa para tratar un ictus isquemico agudo
NO20055880L (no) Memantin orale doseringsformer
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
AR065581A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
AR054249A1 (es) Tratamiento de enfermedades del tejido conectivo de la piel
AR045783A1 (es) Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide
AR065582A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
AR065139A1 (es) Medicamento para el tratamiento de la endometriosis
AR047154A1 (es) Tratamiento del insomnio en pacientes humanos administrandoles una cantidad diaria de gaboxadol
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
AR027394A1 (es) Uso de mirtazapina para el tratamiento de trastornos del sueno
DK1675611T3 (da) Terapeutiske anvendelser for C-peptid
MX2010006310A (es) O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor.
NZ597675A (en) Medicament for the long term nsaid use
AR061046A1 (es) Mirtazapina para el tratamiento del dolor neuropatico
CR8584A (es) Piperazinas derivadas de urea para el tratamiento de la endometrosis

Legal Events

Date Code Title Description
FA Abandonment or withdrawal